(Q39240051)

10 September 2017

title

Class II-specific histone deacetylase inhibitors MC1568 and MC1575 suppress IL-8 expression in human melanoma cells (English)

1 reference

10 September 2017

I Venza

1

1 reference

10 September 2017

M Visalli

2

1 reference

10 September 2017

R Oteri

3

1 reference

10 September 2017

M Cucinotta

4

1 reference

10 September 2017

D Teti

5

1 reference

10 September 2017

M Venza

6

1 reference

10 September 2017

publication date

7 January 2013

1 reference

Pigment Cell & Melanoma Research

10 September 2017

published in

1 reference

10 September 2017

volume

26

1 reference

10 September 2017

issue

2

1 reference

10 September 2017

page(s)

193-204

1 reference

Potentiation of tumor necrosis factor-induced NF-kappa B activation by deacetylase inhibitors is associated with a delayed cytoplasmic reappearance of I kappa B alpha

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

Histone deacetylase inhibitors and malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

Regulation of interleukin-8 gene at a distinct site of its promoter by CCAAT enhancer-binding protein homologous protein in prostaglandin E2-treated human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

Does ocular treatment of uveal melanoma influence survival?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

Impact of histone deacetylase inhibitors SAHA and MS-275 on DNA repair pathways in human mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

Prospects: histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

Specific activity of class II histone deacetylases in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

Deacetylase activity is required for cAMP activation of a subset of CREB target genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

Selenium-containing histone deacetylase inhibitors for melanoma management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

Caprylic acid and medium-chain triglycerides inhibit IL-8 gene transcription in Caco-2 cells: comparison with the potent histone deacetylase inhibitor trichostatin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

Molecular pathogenesis of cutaneous melanocytic neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

Translating the Histone Code

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

Human placenta promotes IL-8 expression through activation of JNK/SAPK and transcription factors NF-kappaB and AP-1 in PMA-differentiated THP-1 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

Histone deacetylase inhibitors exert time-dependent effects on nuclear factor-kappaB but consistently suppress the expression of proinflammatory genes in human myometrial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

Anti-melanoma effects of vorinostat in combination with polyphenolic antioxidant (-)-epigallocatechin-3-gallate (EGCG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

Mechanism of IFN-beta-mediated inhibition of IL-8 gene expression in astroglioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

Chemistry and biology of chromatin remodeling agents: state of art and future perspectives of HDAC inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

Histone deacetylase activity is required to recruit RNA polymerase II to the promoters of selected interferon-stimulated early response genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

Transcriptional regulation of human osteopontin promoter by histone deacetylase inhibitor, trichostatin A in cervical cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

CXCL8 and its cognate receptors in melanoma progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

The language of covalent histone modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFalpha and IL-1alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

Nucleus accumbens-associated 1 contributes to cortactin deacetylation and augments the migration of melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

Evidence for epigenetic mechanisms that silence both basal and immune-stimulated transcription of the IL-8 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

Histone deacetylase inhibitors suppress the induction of c-Jun and its target genes including COX-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

Inhibition of Histone Deacetylase Class I but not Class II Is Critical for the Sensitization of Leukemic Cells to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12049

21 January 2018

Identifiers

DOI

10.1111/PCMR.12049

1 reference

release_3lpwtgog6nerxgp2cdmeq7aopi

10 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3lpwtgog6nerxgp2cdmeq7aopi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference